Utah

Psychedelic trials in Utah

22 registered trials has a study site in Utah, and 1 is recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30

Facilities

Where the research happens in Utah

Facility	City	Trials
Cedar Clinical Research	Draper	10
Huntsman Cancer Institute	Salt Lake City	3
Inner Space Research	Orem	2
University of Utah Health	Salt Lake City	2
University of Utah	Salt Lake City	1
Inner Space Research, LLC	Orem	1
The University of Utah - Huntsman Mental Health Institute	Salt Lake City	1
Cedar Clinical Research, Inc.	Murray	1
Clinical Site 117	Murray	1
Intermountain Medical Center	Murray	1
McKay-Dee Hospital	Ogden	1
Utah Valley Hospital	Provo	1
Primary Children's Hospital	Salt Lake City	1
Cedar Clinical Research - Murray	Murray	1
University Of Utah	Salt Lake City	1
Clinical Site 147	Draper	1
Seelos Investigational Site	Salt Lake City	1
Huntsman Mental Health Institute	Salt Lake City	1

Stay told

When a trial opens in Utah

All trials

Every trial with a Utah site

Trial	Status	Phase	Substance	Sites
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
Comparative Effectiveness of ECT vs. KETAMINE Over the LifespanNCT06034821 · Brigham and Women's Hospital	Enrolling by invitation	Phase 4	ketamine	10
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL Limited	Active, not recruiting	Phase 3	psilocybin	45
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS Pathways	Completed	Phase 3	psilocybin	40
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940 · COMPASS Pathways	Active, not recruiting	Phase 3	psilocybin	116
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	22
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona Institute	Active, not recruiting	Phase 3	psilocybin	29
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	34
Endogenous Opioid Modulation by KetamineNCT03051945 · University of Utah	Withdrawn	Phase 3	ketamine	1
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)NCT06051721 · Cybin IRL Limited	Completed	Phase 2	dmt	6
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderNCT06340958 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	23
KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn InjuryNCT07563296 · Irma Fleming	Not yet recruiting	Phase 2	ketamine	1
A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · Usona Institute	Completed	Phase 2	psilocybin	11
Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)NCT04772222 · University of Utah	Completed	Phase 2	dmt	5
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsNCT05407064 · Definium Therapeutics US, Inc.	Completed	Phase 2	lsd	22
Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery EnhancementNCT07369089 · University of California, San Diego	Not yet recruiting	Phase 2	ketamine	2
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	46
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	13
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of SuicideNCT04669665 · Seelos Therapeutics, Inc.	Completed	Phase 2	ketamine	21
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related BurnoutNCT05557643 · University of Utah	Completed	Phase 1	psilocybin	1
Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI CancersNCT06001372 · University of Utah	Terminated	Early Phase 1	ketamine	1
Study of Psilocybin Enhanced Group Psychotherapy in Patients With CancerNCT04522804 · University of Utah	Completed	Early Phase 1	psilocybin	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere